Results for 'anticancer therapy'
Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation
Oct 11th • 1 min read
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Apr 19th • 7 mins read
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Apr 6th • 12 mins read
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Feb 22nd • 8 mins read
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
Mar 11th • 7 mins read
“Oncometabolism: The switchboard of cancer: An editorial”
Jan 31st • 1 min read
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
Nov 19th • 12 mins read
Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis
Oct 15th • 12 mins read
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Sep 25th • 17 mins read
Leveraging existing data to contextualize phase II clinical trial findings in oncology
Sep 20th • 3 mins read
A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinoma-To Know, Then to Measure
Aug 11th • 10 mins read
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
Sep 5th • 20 mins read
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
Sep 5th • 17 mins read
Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
Aug 30th • 16 mins read
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
Aug 15th • 8 mins read
Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
Jul 21st • 12 mins read
Biosimilars in oncology: key role of nurses in patient education
Jun 14th • 10 mins read